Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra

Neurobiology of Aging

Volumn 25, Issue 9, 2004, Pages 1253-1262

  Van Muiswinkel, F L ^a,d   De Vos, R A I ^b   Bol, J G J M ^a   Andringa, G ^a   Jansen Steur, E N H ^b   Ross, D ^c   Siegel, D ^c   Drukarch, B ^a  

^a Institute for Clinical and Experimental Neurosciences ICEN   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Astrocytes; Dopaminergic neurons; NAD(P)H:quinone oxidoreductase; Neuropathology; Parkinson's disease; Substantia nigra

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

AGED; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MESENCEPHALON; NERVOUS TISSUE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTES; DOPAMINE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA;

EID: 4143150471     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.12.010     Document Type: Article

References (51)

1. Ahlgren-Beckendorf J.A., Reising A.M., Schander M.A., Herdler J.W., Johnson J.A. Coordinate regulation of NAD(P)H:quinone oxidoreductase and glutathione S-transferases in primary cultures of rat neurons and glia: role of the antioxidant/electrophile responsive element. Glia. 25:1999;131-142
2. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M.Y., et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152:1998;879-884
3. Barzilai A., Melamed E., Shirvan A. Is there a rational for neuroprotection against dopamine toxicity in Parkinson's disease. Cell. Mol. Neurobiol. 21:2001;215-235
4. Beyer R.E., Segura-Aguilar J., Di Bernado S., Cavazzoni M., Fato R., Fiorentini D., et al. The two-electron quinone reductase DT-diaphorase generates and maintains the antioxidant (reduced) form of coenzyme Q in membranes. Mol. Aspects Med. 18:1997;s15-23
5. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82:1991;239-259
6. Braak H., Del Tredici K., Rüb U., de Vos R.A.I., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24:2003;197-211
7. Cadenas E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem. Pharmacol. 49:1995;127-140
8. Chan T.S., Teng S., Wilson J.X., Galati G., Khan S., O'Brian P.J. Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H:quinone oxidoreductase (NQO1). Free Radic. Res. 36:2002;421-427
9. Conway K.A., Rochet J.-C., Bieganski R.M., Lansbury P.T. Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α- synuclein adduct. Science. 294:2001;1346-1349
10. Damier P., Hirsch E.C., Zhang P., Agid Y., Javoy-Agid F. Glutathion peroxidase, glial cells and Parkinson's disease. Neuroscience. 52:1993;1-6
11. 28K immunocytochemistry. Brain. 122:1999;1421-1436
12. Dawson T.M., Dawson V.L. Neuroprotective and restorative strategies for Parkinson's disease. Nat. Neurosci. 5:2002;1058-1061
13. Del Tredici K., Rüb U., de Vos R.A.I., Bohl J.R.E., Braak H. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 5:2002;413-426
14. Dhakshinamoorthy S., Long D.J. II, Jaiswal A.K. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr. Topics Cell. Reg. 36:2000;201-216
15. Drukarch B., van Muiswinkel F.L. Drug treatment of Parkinson's disease: time for phase II. Biochem. Pharmacol. 59:2000;1023-1031
16. Drukarch B., van Muiswinkel F.L. Neuroprotection for Parkinsons's disease: a new approach for a new millennium. Expert Opin. Investig. Drugs. 10:2001;1855-1868
17. Drukarch B., Jongenelen C.A., van Muiswinkel F.L. NAD(P)H:quinone oxidoreductase (NQO1) protects astroglial cells against L-Dopa toxicity. Adv. Exp. Med. Biol. 500:2001;237-240
18. Duffy S., So A., Murphy T.H. Activation of endogeneous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J. Neurochem. 71:1998;69-77
19. Graeber M.B., Bise K., Mehraein P. CR3/43, a marker for activated human microglia: application to diagnostic neuropathology. Neuropathol. Appl. Neurobiol. 20:1994;406-408
20. Graumann R., Paris I., Martinez-Alvarado P., Rumanque P., Perez-Pastene C., Cardenas S.P., et al. Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease: possible neuroprotective role of DT-diaphorase. Pol. J. Pharmacol. 54:2002;573-579
21. Harada S., Fujii C., Hayashi A., Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem. Biophys. Res. Commun. 288:2001;887-892
22. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology. 17:1967;427-442
23. Hoozemans J.J.M., Rozemuller A.J.M., Janssen I., de Groot C.J.A., Veerhuis R., Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 101:2001;2-8
24. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:1999;76-86
25. Jaiswal A.K. Antioxidant response element. Biochem. Pharmacol. 48:1994;439-444
26. Kapinya K.J., Harms U., Harms C., Blei K., Katchanov J., Dirnagl U., et al. Role of NAD(P)H:quinone oxidoreductase in the progression of neuronal cell death in vitro and following cerebral ischaemia in vivo. J. Neurochem. 84:2003;1028-1039
27. Kuhn D.M., Arthur R.E., Thomas D.M., Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 73:1999;1309-1317
28. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339:1998;1044-1053
29. Lee J.-M., Calkins M.J., Chan K., Kan Y.W., Johnson J.A. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Sci. 278:2003;12029-12038
30. Li J., Lee J-M., Johnson J.A. Microaray analysis reveals an antioxidant responsive element-driven gene set involved in conferring protection from an oxidative stress-induced apoptosis in IMR-32 cells. J. Biol. Sci. 277:2002;388-394
31. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 47:1996;1113-1124
32. Nguyen T., Sheratt P.J., Pickett C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol. 43:2003;233-260
33. Nguyen T., Sheratt P.J., Huang H.C., Yang C.S., Pickett C.B. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element: degradation of Nrf2 by the 26S proteasome. J. Biol. Chem. 278:2003;4536-4541
34. Orr C.F., Rowe D.B., Halliday G.M. An inflammatory review of Parkinson's disease. Prog. Neurobiol. 68:2002;325-340
35. Picklo M.J., Olson S.J., Hayes J.D., Markesberry W.R., Montine T.J. Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenrative disease. Brain Res. 916:2001;229-238
36. Rescigno A., Rinaldi A.C., Sanjust E. Some aspects of tyrosine secondary metabolism. Biochem. Pharmacol. 56:1998;1089-1096
37. 3+- induced neurotoxicity of dopamine: prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chem. Biol. Interact. 72:1989;309-324
38. Schipper H.M., Liberman A., Stopa E.G. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp. Neurol. 150:1998;60-68
39. Schults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., et al. Effects of coenzyme Q10 in early Parkinson disease. Arch. Neurol. 59:2002;1541-1550
40. Schultzberg M., Segura-Aguilar J., Lind C. Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience. 27:1988;763-776
41. Shao M., Liu Z., Tao E., Chen B. Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene in Parkinson's disease. Zhonghua Yi Xue Za Zhi. 18:2001;122-124
42. Shih A.Y., Johnson D.A., Wong G., Kraft A.D., Jiang L., Erb H., et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci. 23:2003;3394-3406
43. Siegel D., Bolton E.M., Burr J.A., Liebler D.C., Ross D. The reduction of α-tocopherolquinone by human NAD(P)H:quinone oxidoreductase: the role of α-tocopherolhydroquinone as a cellular antioxidant. Mol. Pharmacol. 52:1997;300-305
44. Siegel D., Franklin W.A., Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human lung and lung tumors. Clin. Cancer Res. 4:1998;3083-3088
45. Siegel D., Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic. Biol. Med. 29:2000;246-253
46. Siegel D., Anwar A., Winski S.L., Kepa J.K., Zolman K.L., Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol. Pharmacol. 59:2001;263-268
47. Smythies J., De Iuliis A., Zanatta L., Galzigna L. The biochemical basis of Parkinson's disease: the role of catecholamine o-quinones: a review-discussion. Neurotoxicol. Res. 4:2002;77-81
48. Spencer P.E., Jenner P., Daniel S.E., Lees A.J., Marsden C.D., Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71:1998;2112-2122
49. Stokes A.H., Hastings T.G., Kent K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55:1999;659-665
50. van Muiswinkel F.L., Riemers F.M., Peters G.J., Siegel D., Drukarch B. L-Dopa stimulates expression of the antioxidant enzyme NAD(P)H:quinone oxidoreductase (NQO) in cultured astroglial cells. Free Radic. Biol Med. 29:2000;442-453
51. Wilson J.X. Antioxidant defense of the brain: a role for astrocytes. Can. J. Physiol. Pharmacol. 75:1997;1149-1163